October 31, 2014, 09:57:06 AM *
Welcome, Guest. Please login or register.

Login with username, password and session length
News: NEW SPECIAL SECTION CREATED FOR VIRGINIA AREA MISSING AND MURDERED AND POSSIBLE CONNECTIONS
 
   Home   Help Login Register  
Pages: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 »   Go Down
  Print  
Author Topic: H1N1 - Swine Flu - Novel Flu - Information  (Read 66877 times)
0 Members and 1 Guest are viewing this topic.
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #220 on: July 15, 2009, 06:14:12 PM »

http://www.cdc.gov/h1n1flu/10steps.htm

CDC: 10 Steps You Can Take: Actions for Novel H1N1 Influenza Planning and Response for Medical Offices and Outpatient Facilities

It is critical to assure that medical offices and other outpatient facilities (e.g., outpatient/ambulatory clinics, outpatient surgery centers, urgent care centers, physical therapy/rehabilitation offices or clinics) that provide routine, episodic, and/or chronic healthcare services can manage an increased demand for services in the midst of a novel H1N1 influenza outbreak.  Ensuring a sustainable community healthcare response will be important for a likely recurrence of novel H1N1 flu in the fall. See CDC’s H1N1 website for up-to-date information. 

Read full article>>   

                                        http://www.cdc.gov/h1n1flu/10steps.htm

Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #221 on: July 16, 2009, 01:16:08 PM »


 WHO: Changes in reporting requirements for pandemic (H1N1) 2009 virus infection

16 JULY 2009 | GENEVA -- As the 2009 pandemic evolves, the data needed for risk assessment, both within affected countries and at the global level, are also changing.

At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable.

This assumption is fully backed by experience. The 2009 influenza pandemic has spread internationally with unprecedented speed. In past pandemics, influenza viruses have needed more than six months to spread as widely as the new H1N1 virus has spread in less than six weeks. 

Read full article>>    http://www.who.int/csr/disease/swineflu/notes/h1n1_surveillance_20090710/en/index.html
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #222 on: July 16, 2009, 01:21:10 PM »

Received via e-mail today - 16July2009



CDC: Home Care Guidance Physician Directions to Patient/Parent

This document provides Physician Directions to Patient/Parent for Novel H1N1 Influenza. 

Read full article>>    http://www.cdc.gov/h1n1flu/guidance_homecare_directions.htm

Logged

_
I believe in miracles...!
Toler
Monkey Junky
***
Offline Offline

Posts: 1245



« Reply #223 on: July 16, 2009, 06:11:02 PM »

Time Online July 16, 2009

Britain plans for 65,000 deaths from swine flu
 Sam Lister, Health Editor
36 Comments

The NHS should plan for a worst case scenario of up to 65,000 swine flu deaths this year, the Government said today, as the number of people to die after contracting the virus rose to 29.

Health officials confirmed that a further nine people in England had died after contracting the swine flu virus, following the deaths of a six-year-old schoolgirl and a family doctor. There were unconfirmed reports tonight that another young child — a boy from Kent — may be among the latest victims.

The reports came as Sir Liam Donaldson, the Chief Medical Officer, presented the latest NHS plans for coping with the pandemic. The recommendations, based on 30 per cent of the population falling ill, were issued as latest figures showed that about 55,000 people reported flu symptoms last week.

Sir Liam said it was not yet known whether the latest people to die had any underlying health problems

http://www.timesonline.co.uk/tol/life_and_style/health/article6716477.ece

continued at link
Logged
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #224 on: July 17, 2009, 09:57:26 AM »

http://www.whitehouse.gov/the_press_office/Letter-from-the-President-regarding-H1N1/

 President Obama designates $1.825 billion emergency funds to combat H1N1 threat

THE WHITE HOUSE

Office of the Press Secretary
_________________________________________________________________________
For Immediate Release                                                        July 16, 2009

TEXT OF A LETTER FROM THE PRESIDENT
TO THE SPEAKER OF THE HOUSE OF REPRESENTATIVES

July 16, 2009

Dear Madam Speaker:

On June 24, I signed into law the Supplemental Appropriations Act, 2009 (Public Law 111-32). Within the Act, the Congress appropriated $7.65 billion to the Department of Health and Human Services for the 2009-H1N1 influenza outbreak, including a $5.8 billion contingent appropriation for an influenza pandemic. My Administration appreciates the emergency appropriations that the Congress provided and has initiated the development and procurement of 2009-H1N1 vaccines, is expanding the domestic and international surveillance activities, and is preparing for the possibility that a mass immunization campaign may be needed in the fall.

To enhance our Nation's capability to respond to the potential spread of this outbreak, and in accordance with the appropriation, I hereby designate $1.825 billion of the contingent appropriation as emergency funds required to address critical needs related to emerging influenza viruses (specifically, the virus known as 2009-H1N1). These funds will support additional procurement of adjuvant for dose-sparing of vaccine antigen; immunization campaign planning; regulatory activities for H1N1 at the Food and Drug Administration; and funding for the administration of an injury compensation program.

There remains much uncertainty about the outbreak and its potential to return this fall during the northern hemisphere flu season. We continue to watch the evolution of the 2009-H1N1 virus and the worldwide outbreaks and are working diligently to plan and prepare for a national response, should it be necessary.

We will communicate with you further in the future should additional funds be required.

Sincerely,
BARACK OBAMA

 

Read full article>>   
http://www.whitehouse.gov/the_press_office/Letter-from-the-President-regarding-H1N1/

Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #225 on: July 20, 2009, 11:22:37 AM »

http://www.cdc.gov/h1n1flu/update.htm   Click on link to check your State or territory

CDC Updates U.S. H1N1 Flu Situation: 55 states & territoires | 40,617 cases

U.S. Human Cases of H1N1 Flu Infection
Updated July 17, 2009,
11:00 AM ET
Data reported to CDC by July 17, 2009, 11:00 AM ET.

55 States and territories | 40,617 cases | 263 deaths


 

Full List>>   http://www.cdc.gov/h1n1flu/update.htm
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #226 on: July 21, 2009, 10:09:49 AM »

FDA Approves Vaccine for 2009-2010 Seasonal Influenza

FDA NEWS RELEASE

For Immediate Release: July 20, 2009

FDA Approves Vaccine for 2009-2010 Seasonal Influenza
The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.

The seasonal influenza vaccine will not protect against the 2009 H1N1 influenza virus that resulted in the declaration of a pandemic by the World Health Organization (WHO) on June 11, 2009.  The FDA continues to work with manufacturers, international partners and other government agencies to facilitate the availability of a safe and effective vaccine against the 2009 H1N1 influenza virus.

Although this year’s seasonal vaccine is directed against other strains of influenza expected to be circulating and will not provide protection against the 2009 H1N1 influenza virus, it is still important for those Americans for whom it is recommended to receive the seasonal influenza vaccine. No vaccine is 100 percent effective against preventing disease, but vaccination is the best protection against influenza and can prevent many illnesses and deaths.

“The approval of this year’s seasonal influenza vaccine is an example of the FDA’s important responsibility to assure timely availability of vaccine to help protect the health of the American public,” said Margaret A. Hamburg, M.D., commissioner of food and drugs. “A new seasonal influenza vaccine each year is a critical tool in protecting public health.”

The six vaccine brand names and manufacturers are: Afluria, CSL Limited; Fluarix, GlaxoSmithKline Biologicals; FluLaval, ID Biomedical Corporation; Fluvirin, Novartis Vaccines and Diagnostics Limited; Fluzone, Sanofi Pasteur Inc.; and FluMist, MedImmune Vaccines Inc.

Each year, experts from the FDA, WHO, U.S. Centers for Disease Control and Prevention (CDC), and other institutions study virus samples and patterns collected from around the world in an effort to identify strains that may cause the most illness in the upcoming season.

Based on those forecasts and on the recommendations of the FDA’s Vaccine and Related Products Advisory Committee, the FDA determines the three strains that manufacturers should include in their vaccines for the U.S. population. The closer the match between the circulating strains and the strains in the vaccine, the better the protection against the disease.

The vaccine for the 2009-2010 seasonal influenza contains:

an A/Brisbane/59/2007 (H1N1)-like virus
an A/Brisbane/10/2007 (H3N2)-like virus
a B/Brisbane/60/2008-like virus
There is always a possibility of a less than optimal match between the virus strains predicted to circulate and the virus strains that end up causing the most illness. Even if the vaccine and the circulating strains are not an exact match, the vaccine may reduce the severity of the illness or may help prevent influenza-related complications.

According to the CDC, between 5 percent and 20 percent of the U.S. population develops influenza each year. More than 200,000 are hospitalized from its complications and about 36,000 people die. Older people, young children, and people with chronic medical conditions are at higher risk for influenza-related complications. Vaccination of these groups is critical. 

Additionally, influenza immunization of health care personnel is important in protecting them and others from influenza.

For more information:

FDA Web Page on Influenza Vaccine Safety & Availability
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm110288.htm

FDA List of Strains Included in the 2009-2010 Influenza Vaccine
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm162050.htm

U.S. Centers for Disease Control and Prevention Web Page on Seasonal Influenza Resources for Health Professionals
http://www.cdc.gov/flu/professionals/vaccination/

U.S. Centers for Disease Control and Prevention Web Page with Key Fact About Seasonal Flu Vaccine
http://www.cdc.gov/flu/protect/keyfacts.htm

 

Read full article>>   http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172772.htm

Logged

_
I believe in miracles...!
nonesuche
Monkey All Star Jr.
****
Offline Offline

Posts: 8848



« Reply #227 on: July 21, 2009, 09:08:23 PM »



Airlines stop swine flu victims flying

LONDON, England (CNN) -- British airlines have put into effect measures to stop people with swine flu boarding flights in a bid to prevent the virus from spreading further.....

more here http://www.cnn.com/2009/TRAVEL/07/20/airlines.swine.flu/

A  european professional with my employer died of swine flu this week. Britain is also considering delaying the start of school this fall just to ensure vaccines are available prior which I hope the US considers doing too.

A new plant to manufacture the vaccine was opened 15 miles away, it's my understanding that open clinics will be held in every county for ease of vaccination. I hope all of us take this threat seriously and pursue being vaccinated.

Mere and others, thank you for keeping this thread active with all of your updates, I appreciate it.
Logged

I continue to stand with the girl.
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #228 on: July 23, 2009, 08:44:06 AM »

Questions & Answers: Novel H1N1 Influenza Vaccine (CDC)

Q. What are the plans for developing novel H1N1 vaccine?

A. Vaccines are the most powerful public health tool for control of influenza, and the U.S. government is working closely with manufacturers to take steps in the process to manufacture a novel H1N1 vaccine. Working together with scientists in the public and private sector, CDC has isolated the new H1N1 virus and modified the virus so that it can be used to make hundreds of millions of doses of vaccine. Vaccine manufacturers are now using these materials to begin vaccine production. Making vaccine is a multi-step process which takes several months to complete.  Candidate vaccines will be tested in clinical trials over the few months. 

Q. When is it expected that the novel H1N1 vaccine will be available?

A. The novel H1N1 vaccine is expected to be available in the fall. More specific dates cannot be provided at this time as vaccine availability depends on several factors including manufacturing time and time needed to conduct clinical trials



Q. Will the seasonal flu vaccine also protect against the novel H1N1 flu?

A. The seasonal flu vaccine is not expected to protect against the novel H1N1 flu.

Q. Can the seasonal vaccine and the novel H1N1 vaccine be given at the same time?

A. Clinical trial results will be necessary to confirm that novel H1N1 and seasonal vaccine will be safe and effective if given at the same time. We expect the seasonal vaccine to be available earlier than the H1N1 vaccine. The usual seasonal influenza viruses are still expected to cause illness this fall and winter. Individuals are encouraged to get their seasonal flu vaccine as soon as it is available.

Q. Who will be recommended as priority groups to receive the novel H1N1 vaccine?

A. Based on what we're currently seeing with respect to the virus and epidemiologic data, states, communities, and health care providers should begin planning strategies for how they will vaccinate younger people (children and younger adults), pregnant women, healthcare personnel, and people who have underlying health conditions. The Advisory Committee on Immunization Practices (ACIP) and other federal advisory bodies will continue to monitor the virus and review epidemiologic data over the summer. We'll be looking to the ACIP and other stakeholders, as well as the public, as we move forward in our planning. It is possible that vaccine priority groups will differ from earlier guidance as more data becomes available however it's very important for planning to continue based on information currently available.

Q. Where will the vaccine be available?


A. Every state is developing a vaccine delivery plan. Vaccine will be available in a combination of settings such as vaccination clinics organized by local health departments, healthcare provider offices, schools, and other private settings, such as pharmacies and workplaces.

Q. Are there other ways to prevent the spread of illness?

A. Take everyday actions to stay healthy.

Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hands cleaners are also effective.
Avoid touching your eyes, nose or mouth. Germs spread that way.
Stay home if you get sick. CDC recommends that you stay home from work or school and limit contact with others to keep from infecting them.


Follow public health advice regarding school closures, avoiding crowds and other social distancing measures. These measures will continue to be important after a novel H1N1 vaccine is available because they can prevent the spread of other viruses that cause respiratory infections.

Q. What about the use of antivirals to treat novel H1N1 infection?

A. Antiviral drugs are prescription medicines (pills, liquid or an inhaled powder) that fight against the flu by keeping flu viruses from reproducing in your body. If you get sick, antiviral drugs can make your illness milder and make you feel better faster. They may also prevent serious flu complications. This fall, antivirals may be prioritized for persons with severe illness or those at higher risk for flu complications.

Read full article>>  http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm


 
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #229 on: July 23, 2009, 08:50:18 AM »

NIAID Set to Launch Clinical Trials to Test 2009 H1N1 Influenza Vaccine Candidates

Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
"With the emergence of the 2009 H1N1 influenza virus, we have undertaken a collaborative and efficient process of vaccine development that is proceeding in stepwise fashion," says NIAID Director Anthony S. Fauci, M.D.

After the isolation and characterization of the virus, the U. S. Centers for Disease Control and Prevention generated and distributed a 2009 H1N1 seed virus to vaccine manufacturers for the development of vaccine pilot lots for testing in clinical trials.

"Now, NIAID will use our longstanding vaccine clinical trials infrastructure — the Vaccine and Treatment Evaluation Units — to help quickly evaluate these pilot lots to determine whether the vaccines are safe and to assess their ability to induce protective immune responses," says Dr. Fauci. "These data will be factored into the decision about how and if to implement a 2009 H1N1 flu immunization program this fall."

Initial studies will look at whether one or two 15 microgram doses of H1N1 vaccine are needed to induce a potentially protective immune response in healthy adult volunteers (aged 18 to 64 years old) and elderly people (aged 65 and older). Researchers also will assess whether one or two 30 microgram doses are needed. The doses will be given 21 days apart, testing two manufacturers’ vaccines (Sanofi Pasteur and CSL Biotherapies). If early information from those trials indicates that these vaccines are safe, similar trials in healthy children (aged 6 months to 17 years old) will begin.

A concurrent set of trials will look at the safety and immune response in healthy adult and elderly volunteers who are given the seasonal flu vaccine along with a 15 microgram dose of 2009 H1N1 vaccine. The H1N1 vaccine would be given to different sets of volunteers either before, after, or at the same time as the seasonal flu vaccine. If early information from those studies indicates that these vaccines are safe, similar trials in healthy children (aged 6 months to 17 years old) will start.

A panel of outside experts will conduct a close review of the safety data from these trials to spot any safety concerns in real time. Information from these studies in healthy people will help public health officials develop recommendations for immunization schedules, including the optimal dosage and number of doses for multiple age and groups, including adults, the elderly, and children. Data may also be used to support decisions about the best recommendations for people in high risk groups, including pregnant women and people whose immune systems are weakened or otherwise compromised.

The trials are being conducted in a compressed timeframe in a race against the possible autumn resurgence of 2009 H1N1 flu infections that may occur at the same time as seasonal influenza virus strains begin to circulate widely in the Northern Hemisphere.

Close collaboration among NIAID, the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (a component of the Department of Health and Human Services) was key to launching the trials quickly while ensuring high standards. Following initial discussions between the agencies on trial design, NIAID prepared the protocols and submitted them to the FDA for review. FDA rapidly completed the necessary reviews and approved the trial protocols.

Since 1962, NIAID’s Vaccine and Treatment Evaluation Units (VTEUs) have been intensively involved in the successful development and clinical testing of vaccines and treatments against many pathogens that threaten the health of people in the United States and around the world. Among the vaccines tested have been those that prevent seasonal influenza, H5N1 avian influenza and pneumococcal pneumonia.

The VTEU network consists of eight university research hospitals and medical organizations across the United States that provide a ready resource for conducting clinical trials that evaluate vaccines and treatments for a wide array of infectious diseases.

An important strength of the VTEUs is their ability to rapidly enroll large numbers of volunteers into trials and to immunize the volunteers in a safe, effective and efficient manner. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns. Results are expected to be available weeks after the trials begin.

NIAID’s Vaccine and Treatment Evaluation Units include the following:

Baylor College of Medicine, Houston
Children’s Hospital Medical Center, Cincinnati
Emory University, Atlanta
Group Health Cooperative, Seattle
Saint Louis University, St. Louis
University of Iowa, Iowa City
University of Maryland School of Medicine, Baltimore
Vanderbilt University, Nashville, Tenn.
Further information about the five trials can be found at ClinicalTrials.gov at the following links:

09-0053 Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Given at Two Dose Levels to Healthy Adult and Elderly Populations
NCT00943631 (http://clinicaltrials.gov/show/NCT00943631)

09-0043 Unadjuvanted CSL H1N1 Influenza Vaccine Given at Two Dose Levels to Healthy Adult and Elderly Populations
NCT00943488 (http://clinicaltrials.gov/show/NCT00943488)

09-0039 Licensed Seasonal Flu Vaccine Given Together or Sequentially with Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations
NCT00943878 (http://clinicaltrials.gov/show/NCT00943878)

09-0054 Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels to Children
NCT00944073 (http://clinicaltrials.gov/show/NCT00944073)

09-0047 Licensed Seasonal Flu Vaccine Given Together or Sequentially with Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Children
NCT00943202 (http://clinicaltrials.gov/show/NCT00943202)
For more information on influenza, visit www.flu.gov for one-stop access to U.S. government information on avian and pandemic influenza. Also, see http://www3.niaid.nih.gov/topics/Flu/.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
 

Read full article>>   http://www.nih.gov/news/health/jul2009/niaid-22.htm

Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #230 on: July 23, 2009, 09:35:11 AM »

WHO will no longer issue the global tables showing the numbers of confirmed cases for all countries

Pandemic (H1N1) 2009 briefing note 3 (revised)

Changes in reporting requirements for pandemic (H1N1) 2009 virus infection


16 JULY 2009 | GENEVA -- As the 2009 pandemic evolves, the data needed for risk assessment, both within affected countries and at the global level, are also changing.

At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable.

This assumption is fully backed by experience. The 2009 influenza pandemic has spread internationally with unprecedented speed. In past pandemics, influenza viruses have needed more than six months to spread as widely as the new H1N1 virus has spread in less than six weeks.

The increasing number of cases in many countries with sustained community transmission is making it extremely difficult, if not impossible, for countries to try and confirm them through laboratory testing. Moreover, the counting of individual cases is now no longer essential in such countries for monitoring either the level or nature of the risk posed by the pandemic virus or to guide implementation of the most appropriate response measures.

Monitoring still needed
This pandemic has been characterized, to date, by the mildness of symptoms in the overwhelming majority of patients, who usually recover, even without medical treatment, within a week of the onset of symptoms. However, there is still an ongoing need in all countries to closely monitor unusual events, such as clusters of cases of severe or fatal pandemic (H1N1) 2009 virus infection, clusters of respiratory illness requiring hospitalization, or unexplained or unusual clinical patterns associated with serious or fatal cases.

Other potential signals of change in the currently prevailing pattern include unexpected, unusual or notable changes in patterns of transmission. Signals to be vigilant for include spikes in rates of absenteeism from schools or workplaces, or a more severe disease pattern, as suggested by, for example, a surge in emergency department visits.

In general, indications that health services are having difficulty coping with cases mean that such systems are under stress but they may also be a signal of increasing cases or a more severe clinical picture.

A strategy that concentrates on the detection, laboratory confirmation and investigation of all cases, including those with mild illness, is extremely resource-intensive. In some countries, this strategy is absorbing most national laboratory and response capacity, leaving little capacity for the monitoring and investigation of severe cases and other exceptional events.

Regular updates on newly affected countries
For all of these reasons, WHO will no longer issue the global tables showing the numbers of confirmed cases for all countries. However, as part of continued efforts to document the global spread of the H1N1 pandemic, regular updates will be provided describing the situation in the newly affected countries. WHO will continue to request that these countries report the first confirmed cases and, as far as feasible, provide weekly aggregated case numbers and descriptive epidemiology of the early cases.

For countries already experiencing community-wide transmission, the focus of surveillance activities will shift to reporting against the established indicators for the monitoring of seasonal influenza activity. Those countries are no longer required to submit regular reports of individual laboratory-confirmed cases to WHO.

Monitoring the virological characteristics of the pandemic virus will be important throughout the pandemic and some countries have well-established laboratory-based surveillance systems in place already for seasonal influenza virus monitoring. Even in countries with limited laboratory capacity, WHO recommends that the initial virological assessment is followed by the testing of at least 10 samples per week in order to confirm that disease activity is due to the pandemic virus and to monitor changes in the virus that may be important for case management and vaccine development.

Updated WHO guidelines for global surveillance reflect in greater detail these recommended changes, in line with reporting requirements set out in the International Health Regulations.

 http://www.who.int/csr/disease/swineflu/notes/h1n1_surveillance_20090710/en/index.html
Logged

_
I believe in miracles...!
Nut44x4
Maine - USA
Asst Moderator
Monkey Mega Star
*
Offline Offline

Posts: 18181


...and Injustice for most


« Reply #231 on: July 23, 2009, 11:24:37 AM »

American woman infected with A/H1N1 dies in Philippines
2009-07-23 09:43:20

MANILA, July 23 (Xinhua) -- A 60-year-old American woman died of cardiac arrest in hospital in the eastern Philippines after testing positive for the A/H1N1 flu, media reports said on Thursday.

    The patient died Tuesday night in Tacloban City, Leyte province, the Philippine Star daily reported.

    Dr. Edgardo Gonzaga, a regional director of the Philippine Department of Health, said that Linda Seavey, a teacher at an international school in Leyte, underwent gallbladder surgery before she caught flu.

    "But of course we cannot discount possibilities that her death has complication with H1N1 virus," the official was quoted.

    It was the fifth death related to the Influenza A/H1N1 virus.

    Globally, the World Health Organization has placed the worldwide A/H1N1 death toll at over 700.

http://news.xinhuanet.com/english/2009-07/23/content_11757561.htm
Logged

Brothers and Sisters, I bid you beware/Of giving your heart to a dog to tear  -- Rudyard Kipling
Nut44x4
Maine - USA
Asst Moderator
Monkey Mega Star
*
Offline Offline

Posts: 18181


...and Injustice for most


« Reply #232 on: July 23, 2009, 11:30:44 AM »

Prince William Co. Woman Dies From H1N1 Flu Complications

RICHMOND, Va. (AP) -- Virginia health officials say a woman diagnosed with H1N1 flu has died.

State Health Commissioner Karen Remley said Wednesday that while the cause of death as not been confirmed, the H1N1 virus appears to have been a factor. The woman from the Prince William Health District had an underlying medical condition that put her at greater risk of complications from the flu.

At least three Virginians have died from the virus since early June.

The Centers for Disease Control and Prevention reports 263 deaths caused by the H1N1 flu nationally.
http://www.wusa9.com/rss/local_article.aspx?storyid=88858
Logged

Brothers and Sisters, I bid you beware/Of giving your heart to a dog to tear  -- Rudyard Kipling
Nut44x4
Maine - USA
Asst Moderator
Monkey Mega Star
*
Offline Offline

Posts: 18181


...and Injustice for most


« Reply #233 on: July 23, 2009, 12:48:19 PM »

Flu A/H1N1-related deaths on rise in Asia-Pacific region 
 
www.chinaview.cn  2009-07-23 23:59:11     
 
    HONG KONG, July 23 (Xinhua) -- The deaths related to flu A/H1N1have been on a rise in the Asia-Pacific region as more countries have reported an increasing number of fatalities.

    On Thursday, Malaysia and Laos each reported its first death case in connection with the flu. So far, Australia, New Zealand, Thailand, the Philippines and China's Hong Kong had also reported deaths related to the new flu virus.

    Australia's fatalities of such cases have hit 45, which is followed by Thailand with 44 and New Zealand with 14.

    According to the Health Ministry of Malaysia on Thursday, an Indonesian student who had been infected with A/H1N1 flu was dead in Malaysia.

    The student, in his 30s, died from cardiac arrest, instead of the flu virus, Malaysian Health Minister Liow Tiong Lai said.

    Although the virus was found in the body, no evidence showed that the cause of death lay with it, the minister said.

    The student was reportedly from the International Center for Education in Islamic Finance in the capital. He suffered from obesity problem and had an enlarged heart and liver.

    Sin Chew Daily, a Chinese-language newspaper, said that the student was brought to a private hospital when he was suffering from dyspnea on Tuesday, but he died two or three hours later when he was waiting for his medicine.

    In Laos, a 31-year-old man was confirmed to have died of A/H1N1flu, the first death related to the flu in the country, the Vientiane Times reported Thursday.

    The man, not identified by the report, had a history of respiratory problems, obesity and diabetes. He was also a heavy smoker and drinker.

    Lifestyle-related factors could lower the man's immunity to theA/H1N1 virus, said Bounlay Phommasack, head of Lao National Emerging Infection Disease Coordination Office.

    According to his family, the man had never been abroad before. He showed flu-like symptoms on July 9 and was transferred from a provincial hospital to Lao capital city of Vientiane on July 17. The man died later that day.

    Other family members of the man were tested negative for the A/H1N1 virus, said the newspaper.

    So far, Laos has reported 56 influenza A/H1N1 cases.

    Australia's A/H1N1 flu death toll has reached 45 on Thursday, following the death of a 77 year-old Tasmanian woman.

    Tasmania Health department spokesman Gershu Paul said the woman had also suffered from a number of chronic conditions.

    Paul said that although influenza was not the primary cause of the woman's death, it may have been a contributing factor.

    The authorities in New Zealand said A total of 14 people have died in influenza A/H1N1 related disease, New Zealand media reported on Thursday.

    The latest fatalities have been two men, aged 28 and 39, and a Auckland woman, 30, all in Auckland.

    The office of chief coroner Neil MacLean said they were still investigating the deaths.

    But the Ministry of Health said the official death rate from influenza A/H1N1 was 11. All the dead had underlying health conditions.

    New Zealand's influenza A/H1N1 confirmed cases rose to 2,525 on Thursday.

    A spokesman for Hong Kong Department of Health said there had been 116 newly confirmed cases of A/H1N1 influenza on Thursday, bringing the region's tally to 2,207.

    The neighboring Macao reported four newly confirmed cases on same day, taking the total number of such cases to 143 so far.

    According to the statistics from Macao's health bureau, some 22patients who tested positive for the virus were still receiving medical treatment at local hospitals, all in stable condition.

    The Vietnamese Ministry of Health confirmed 32 more influenza A/H1N1 cases on Thursday, raising the country's tally to 475.

    So far, 332 patients have recovered and been discharged from hospitals. The rest are being quarantined and treated, all in stable conditions.
 
http://news.xinhuanet.com/english/2009-07/23/content_11762219.htm
Logged

Brothers and Sisters, I bid you beware/Of giving your heart to a dog to tear  -- Rudyard Kipling
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #234 on: July 24, 2009, 02:50:28 AM »

Swine Flu 'Patient Zero' Found in Mexico
Friday, July 24, 2009 


Print
ShareThis
The world's first known swine flu victim was a six-month-old baby girl in northern Mexico who had no known contact with pig farms, the head of a laboratory studying the virus said on Thursday.

"It's a six-month-old baby girl from San Luis Potosi who is alive" said Celia Alpuche of the Institute of Epidemiological Diagnosis and Reference (INDRE) in Mexico City.

The little girl first showed symptoms of the new strain of the influenza A(H1N1) virus on February 24, she said.

International attention has focused on two possible 'patient zeros', including a five-year-old boy who lived near a pig farm in eastern Mexico and a woman from Oaxaca, in the southeast, after the government first raised the A(H1N1) alert three months ago.

Both had contracted the virus, which has now killed more than 700 people worldwide, in April.

But studies carried out on a backlog of samples show that a first handful of recorded cases appeared in March in central and northern Mexico, before any showed up further south, said Alpuche.

"We have other positive samples in March from Baja California (northwest), San Luis Potosi and Mexico City (center)," Alpuche said, referring to results discovered around one month ago.

Click here to continue reading at the Times of London.

http://www.timesonline.co.uk/tol/news/uk/health/Swine_flu/article6725830.ece
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #235 on: July 24, 2009, 10:42:56 AM »

http://www.cdc.gov/h1n1flu/guidelines_pig_workers.htm

CDC: Interim Guidance for People who have Close Contact with Pigs in Non-commercial Settings

As of June 26, 2009, the novel influenza A (H1N1) virus has not been found in any pigs within the United States, but has been detected in pigs on a farm in Alberta, Canada. This interim guidance is issued with the goal of preventing the spread of this novel virus or any other influenza (flu) virus from people to pigs and from pigs to people.

The following interim recommendations are based on what are deemed minimal precautions for protecting people exposed to pigs known or suspected to have influenza on premises not used for commercial production (e.g. small backyard or hobby farms, zoo settings including petting zoos, homes with pet pigs) AND for protecting pigs from people with influenza.   

Read full article>>   http://www.cdc.gov/h1n1flu/guidelines_pig_workers.htm
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #236 on: July 27, 2009, 12:39:39 PM »

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm173543.htm

FDA Authorizes Emergency Use of Another Test for 2009 H1N1 Influenza Virus

FDA NEWS RELEASE
For Immediate Release: July 24, 2009
 
Consumer Inquiries: 888-INFO-FDA
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #237 on: July 27, 2009, 12:45:53 PM »

CDC: Questions and Answers About Novel H1N1 Influenza Vaccine

Tue, 21 Jul 2009 14:00:00 -0500

Questions and Answers About Novel H1N1 Influenza Vaccine

Read entire article:  http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm




Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #238 on: July 27, 2009, 12:51:15 PM »

FDA Approves Vaccine for 2009-2010 Seasonal Influenza

Mon, 20 Jul 2009 14:00:00 -0500

The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.

Please note:  This is an article about SEASONAL flu vaccine.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172772.htm
Logged

_
I believe in miracles...!
Mere
Monkey Junky
***
Offline Offline

Posts: 3340



« Reply #239 on: July 27, 2009, 12:55:34 PM »

FDA Authorizes Emergency Use of Another Test for 2009 H1N1 Influenza Virus

Fri, 24 Jul 2009 20:00:00 -0500

The U.S. Food and Drug Administration today announced it has issued an Emergency Use Authorization (EUA) for a another diagnostic test for the 2009 H1N1 influenza virus, whose spread has caused the virus to be characterized as a pandemic by the World Health Organization. The EUA for the Focus Diagnostics Influenza H1N1 (2009) Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) diagnostic test is the third diagnostic test authorized under an EUA by the FDA since the public health emergency involving the 2009 H1N1 influenza virus was declared on April 26, 2009.

Read article:  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm173543.htm

Logged

_
I believe in miracles...!
Pages: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 »   Go Up
  Print  
 
Jump to:  

Use of this web site in any manner signifies unconditional acceptance, without exception, of our terms of use.
Powered by SMF 1.1.13 | SMF © 2006-2011, Simple Machines LLC
 
Page created in 0.138 seconds with 19 queries.